marijuana stocks

Cara Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017

Cara Therapeutics, Inc. (CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017, at 4:30 p.m. ET to report fourth quarter and full year 2016 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 70053458. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$NEWC Introduces the New Sannabis Medical Marijuana Product Design

New Colombia Resources, Inc. Introduces the New Sannabis Medical Marijuana Product Design…

Zoned Properties®, Inc. (ZDPY) Announces Final Completion of Expansion at Chino Valley Cultivation Facility

Zoned Properties Announces Final Completion of Expansion at Chino Valley Cultivation Facility…

 InMed Pharmaceuticals Inc. (IMLFF) Files Patent Application for INM-085 Glaucoma Program

InMed Files Patent Application for INM-085 Glaucoma Program  InMed Pharmaceuticals Inc. (“InMed” or…

TILT Holdings Inc. (TLLTF) Enters into Exclusive Manufacture and Distribution Agreement with Curaleaf International

TILT Holdings Enters into Exclusive Manufacture and Distribution Agreement with Curaleaf International…